Shots:

• The P-III ANDROMEDA (AMY3001) study involves assessing of Daratumumab (SC) + cyclophosphamide + bortezomib + dexamethasone (CyBorD) vs CyBorD as monothx. in 388 patients newly diagnosed with AL amyloidosis- conducted by Janssen
• The P-III ANDROMEDA study resulted in meeting its 1EPs of the percentage of patients with hematologic complete response (53.3% vs 18.1%)- the safety profile is in consistent with the known safety profile of the CyBorD regimen and the known safety profile of daratumumab
• In 2012- Genmab granted Janssen an exclusive WW license to develop- manufacture- and commercialize daratumumab. Janssen will discuss data with health authorities to prepare for regulatory filings

 ­ Ref: Genmab | Image: Genmab